AC
CERO

Armistice Capital’s CERo Therapeutics CERO Stock Holding History

Armistice Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,600
Closed -$228K – 281
2025
Q1 		$228K Buy
+15,600
New +$616K ﹤0.01% 198

Other funds holding CERO

PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armistice Capital's CERO Position: Q2 2025 in Review

Armistice Capital sold out of CERo Therapeutics (CERO) in Q2 2025, closing a stake of 15,600 shares — an estimated $228K sold.

Armistice Capital first reported a position in CERO in Q1 2025 and held it in 1 quarter. The position peaked at $228K in Q1 2025. 8 funds tracked by Wall St. Rank hold CERO as of Q2 2025.

  • Armistice Capital reported no remaining CERo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 15,600 CERo Therapeutics shares in Q2 2025, an estimated $228K.
  • Armistice Capital first reported a position in CERo Therapeutics in Q1 2025 and held it in 1 quarter.
  • Armistice Capital's CERo Therapeutics position peaked at $228K in Q1 2025.
  • 8 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.